A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
A phase 2 trial of Lurbinectedin, Durvalumab in small-cell lung cancer, run by Jazz Pharmaceuticals, now recruiting.
Overview
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC is a phase 2 interventional study registered as NCT07459634 by Jazz Pharmaceuticals, with 50 participants planned, started 2026-11-30 and due to reach its primary completion in 2028-01-31. Interventions recorded: Lurbinectedin, Durvalumab. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Shares Lurbinectedin, Jazz Pharmaceuticals.
- TrialATLANTIS
Shares Lurbinectedin, Small-cell lung cancer.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, Small-cell lung cancer.
- TrialIMforte
Shares Lurbinectedin, Small-cell lung cancer.
- TrialStudy to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,
Shares Durvalumab, Small-cell lung cancer.
- TrialBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Shares Lurbinectedin, Small-cell lung cancer.
- TrialIDeate-Lung02
Shares Lurbinectedin, Small-cell lung cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv
Shares Durvalumab, Small-cell lung cancer.